{"brief_title": "An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)", "brief_summary": "The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).", "condition": "Chronic Renal Insufficiency", "intervention_type": "Drug", "intervention_name": "Placebo to glipizide", "description": "One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.", "arm_group_label": "Sitagliptin", "other_name": "MK0431", "criteria": "Inclusion Criteria: - Patients who are at least 18 years of age diagnosed with type 2 diabetes mellitus (T2DM) (a specific type of diabetes). - Patient has renal (kidney) insufficiency (inadequate kidney function) Exclusion Criteria: - Patient has had heart problems (such as a heart attack or chest pain) or stroke within the past 6 months or any condition or therapy which, in the opinion of the investigator, may not be in the patient's best interest to participate. - Pregnant or breast feeding", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00095056.xml"}